Medicenna Therapeutics Preparing for ESMO Congress Presentation
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), an innovative clinical-stage immunotherapy company, is gearing up to present updated clinical data on its groundbreaking MDNA11 therapy during a reputable conference focused on immuno-oncology. This presentation is set for the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025, which will occur in December.
Details About the ABILITY-1 Study
The Phase 1/2 ABILITY-1 Study has been instrumental in evaluating MDNA11, regarded as a next-generation IL-2 therapy, both as a standalone treatment and in conjunction with pembrolizumab. Dr. André Mansinho, the principal investigator for the trial, will share impactful findings from this important study.
Presentation Information
Key details regarding the upcoming presentation include:
Title: ABILITY-1, an innovative analysis of MDNA11, a next-generation IL-2 agonist, whether used alone or with pembrolizumab in advanced solid tumors: interim analysis.
Presenter: Dr. André Mansinho, MD MSc, Assistant Professor at the Faculty of Medicine in Lisbon.
Date: Set for December 10, with high expectations from the scientific community.
MDNA11: A Look into the Innovation
MDNA11 stands out for its unique ability to preferentially activate cancer-fighting T cells and NK cells while having a high affinity for CD122 (IL-2 receptor beta) and avoiding CD25 (IL-2 receptor alpha) binding. This innovative approach aims at maximizing therapeutic benefits in patients with advanced solid tumors.
The Future of IL-2 Therapies
Medicenna is not only focused on MDNA11; the company is also advancing other promising therapeutics. MDNA113, which targets PD-1 and IL-2, exemplifies the company's pursuit of synergistic immunotherapies designed through proprietary platforms. These platforms, BiSKITs™ and T-MASK™, indicate Medicenna's commitment to pioneering immunotherapy solutions.
Empowered Superkines and Clinical Advancements
The company is also working on bizaxofusp, known for its Empowered Superkine characteristics. This therapy has been explored through multiple clinical trials, including a Phase 2b study targeting recurrent glioblastoma, considered one of the most aggressive brain cancers. The focus on transformative therapies reflects Medicenna's dedication to addressing significant unmet medical needs.
Staying Updated
After the presentation at the ESMO Congress, a comprehensive record of the results will be accessible through Medicenna's official channels, allowing continued engagement with the latest advancements in immunotherapy and clinical research. Keeping abreast of ongoing developments is crucial for stakeholders and researchers interested in the future of cancer treatment.
Investor and Media Relations
For inquiries, investors and media representatives can connect with Medicenna directly:
Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
ir@medicenna.com
Frequently Asked Questions
What is MDNA11?
MDNA11 is a next-generation IL-2 therapy designed to target and stimulate the immune system's cancer-fighting capabilities.
When will the presentation on MDNA11 occur?
The presentation is scheduled for December 10, 2025, at the ESMO Immuno-Oncology Congress.
Who is presenting the clinical data?
Dr. André Mansinho, Assistant Professor at the Faculty of Medicine, will present the clinical data.
What is the significance of the ABILITY-1 Study?
The ABILITY-1 Study evaluates MDNA11, focusing on its efficacy as a monotherapy and in combination with pembrolizumab in advanced solid tumors.
How can I learn more about Medicenna's research and updates?
Visit Medicenna’s official website for more information and the latest developments in their clinical research.
